Nektar TherapeuticsNKTR
13F holders, Q4 2025 (December 31)8holders −1
1new positions
1sold out
$42.27avg. 13F price*
At the end of Q4 2025, 8 institutions reported holding Nektar Therapeutics (NKTR) in their 13F filings, down 1 from Q3 2025. 1 opened new positions and 1 sold out. The largest holders were 49 Wealth Management, LLC ($230K), Parallel Advisors, LLC ($45K) and Farther Finance Advisors, LLC ($6K).
- Company
- Nektar Therapeutics
- CUSIP
- 640268108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $6K |
| Exits | 1 | $4K |
All 13F filers, Q3 2025 → Q4 2025: 165 shares bought and 620 shares sold, net −455 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| 49 Wealth Management, LLC | 0.02% | Reduce -9.2% | 5,430 | $230K |
| Parallel Advisors, LLC | 0.00% | No change | 1,053 | $45K |
| Farther Finance Advisors, LLC | 0.00% | New | 141 | $6K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 110 | $5K |
| Nova Wealth Management, Inc. | 0.00% | Add +150.0% | 40 | $2K |
| Fortitude Family Office, LLC | 0.00% | No change | 21 | $888 |
| LRI Investments, LLC | 0.00% | No change | 1 | $42 |
| Huntington National Bank | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is NKTR's weight in each manager's 13F, not the share of Nektar Therapeutics the manager owns.